Basic & Clinical Medicine ›› 2023, Vol. 43 ›› Issue (5): 852-856.doi: 10.16352/j.issn.1001-6325.2023.05.0852

• Mini Reviews • Previous Articles     Next Articles

Research progress of NT5C2 in disease and treatment

SHU Ling, HUO Bennian, SONG Lin*   

  1. Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
  • Received:2022-03-14 Revised:2022-06-29 Online:2023-05-05 Published:2023-04-26
  • Contact: *

Abstract: Cytosolic 5'-nucleotidase Ⅱ(cN-Ⅱ), the protein encoded by NT5C2, can catalyze the dephosphory-lation of nucleoside monophosphate and is mainly involved in the regulation of purine nucleotide pool in cells. High expression of cN-Ⅱ mRNA is associated with poor prognosis of patients with acute leukemia (AL). Acquired NT5C2 mutation will hinder the formation of DNA and thioguanine nucleotide (TGN) conjugate, resulting in 6-mercaptpurine(6-MP) resistance. In addition, NT5C2 is a risk factor associated with type Ⅱ diabetes, schizophrenia and other diseases.

Key words: NT5C2, cytosolic 5'-nucleotidase Ⅱ(cN-Ⅱ), nucleoside analogue, acute leukemia(AL), type 2 diabetes

CLC Number: